NovoCure Limited (NVCR)
NasdaqGS
Price as at 30 Sept 2026, 21:56 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
NovoCure Limited trades at $15.95. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About NovoCure Limited
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Politician trades in NVCR
Trades in NVCR disclosed by members of Congress and executive-branch officials, latest first:
- Donna Shalala · HouseSell · $1,001 - $15,000 · traded 24 Jun 2019 · disclosed 27 Apr 2020
- Donna Shalala · HouseBuy · $1,001 - $15,000 · traded 19 Jun 2019 · disclosed 27 Apr 2020
A disclosure reports a value band, not an amount, and is due up to 45 days after the trade; some arrive later. Every filer we track, each with their own page, is on the Congress trading tracker.
Common questions
Where does SteadyShares get its NVCR data?
Fundamentals for NVCR come from company filings and exchange data, as listed on NasdaqGS; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 30 Sept 2026, 21:56 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for NVCR, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.